Top

Published in:

01-12-2014 | Translational Research and Biomarkers

Loss of CDCP1 Expression Promotes Invasiveness and Poor Prognosis in Esophageal Squamous Cell Carcinoma

Authors: Genta Sawada, MD, Yusuke Takahashi, MD, Atsushi Niida, PhD, Teppei Shimamura, PhD, Junji Kurashige, MD, Tae Matsumura, MD, Hiroki Ueo, MD, Ryutaro Uchi, MD, Yuki Takano, MD, Masami Ueda, MD, Hidenari Hirata, MD, Shotaro Sakimura, MD, Yoshiaki Shinden, MD, Hidetoshi Eguchi, MD, PhD, Tomoya Sudo, MD, PhD, Keishi Sugimachi, MD, PhD, Satoru Miyano, PhD, Yuichiro Doki, MD, PhD, Masaki Mori, MD, PhD, FACS, Koshi Mimori, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 4/2014

Abstract

Background

Human CDCP1 gene, located on chromosome 3p21.3, is a transmembrane glycoprotein widely expressed in epithelial tissues, and its role in cancer remains to be understood.

Methods

Using microarray profiles of gene expression and copy number data from 69 esophageal squamous cell carcinoma (ESCC) samples, we performed informatics analyses to reveal the significance of CDCP1 expression. We also performed migration and invasion assays of siRNA-targeted CDCP1-transfected cells and CDCP1-overexpressing cell in vitro. Moreover, we evaluated the clinical magnitude of CDCP1 expression in esophageal squamous cell cancer cases.

Results

Allelic loss of chromosome 3p was confirmed by copy number analysis. The expression level of CDCP1 in tumor tissue was significantly lower than that in corresponding normal tissue. siRNA targeting of CDCP1 promoted the migratory and invasive abilities of esophageal cancer cell lines, whereas both abilities were reduced in CDCP1-overexpressing cells. Gene set enrichment analysis showed that expression levels of CDCP1 were associated with tumor differentiation and metastasis, consistent with the result of clinicopathologic analyses. Finally, multivariate analysis revealed that the expression level of CDCP1 was an independent prognostic factor for survival.

Conclusions

Loss of CDCP1 expression may be a novel indicator for biological aggressiveness in ESCC.

Available only for authorised users

Maehara Y, Orita H, Okuyama T, et al. Predictors of lymph node metastasis in early gastric cancer. Br J Surg. 1992;79:245–7.PubMedCrossRef

Kawamura YJ, Sakuragi M, Togashi K, Okada M, Nagai H, Konishi F. Distribution of lymph node metastasis in T1 sigmoid colon carcinoma: should we ligate the inferior mesenteric artery? Scand J Gastroenterol. 2005;40:858–61.PubMedCrossRef

Goel HL, Languino LR. Integrin signaling in cancer. Cancer Treat Res. 2004;119:15–31.PubMedCrossRef

Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010;29:223–37.PubMedCrossRef

Spassov DS, Wong CH, Sergina N, et al. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011;31:766–82.PubMedCentralPubMedCrossRef

Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013;73:1168–79.PubMedCentralPubMedCrossRef

Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol. 2007;27:7649–60.PubMedCentralPubMedCrossRef

Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA. 2007;104:20007–12.PubMedCentralPubMedCrossRef

Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.PubMedCentralPubMedCrossRef

10.

Schafer M, Schwender H, Merk S, Haferlach C, Ickstadt K, Dugas M. Integrated analysis of copy number alterations and gene expression: a bivariate assessment of equally directed abnormalities. Bioinformatics. 2009;25:3228–35.PubMedCrossRef

11.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.PubMedCentralPubMedCrossRef

12.

Huebner K. Tumor suppressors on 3p: a neoclassic quartet. Proc Natl Acad Sci USA. 2001;98:14763–5.PubMedCentralPubMedCrossRef

13.

Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 2000;60:6116–33.PubMed

14.

Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–42.PubMedCentralPubMedCrossRef

15.

Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene. 2001;20:4402–8.PubMedCrossRef

16.

Miyazawa Y, Uekita T, Hiraoka N, et al. CUB domain–containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 2010;70:5136–46.PubMedCrossRef

17.

Spassov DS, Wong CH, Harris G, et al. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012;31:419–31.PubMedCentralPubMedCrossRef

18.

Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005;24:5333–43.PubMedCentralPubMedCrossRef

19.

Liu H, Ong SE, Badu-Nkansah K, Schindler J, White FM, Hynes RO. CUB-domain-containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci USA. 2011;108:1379–84.PubMedCentralPubMedCrossRef

Title: Loss of CDCP1 Expression Promotes Invasiveness and Poor Prognosis in Esophageal Squamous Cell Carcinoma
Authors: Genta Sawada, MD
Yusuke Takahashi, MD
Atsushi Niida, PhD
Teppei Shimamura, PhD
Junji Kurashige, MD
Tae Matsumura, MD
Hiroki Ueo, MD
Ryutaro Uchi, MD
Yuki Takano, MD
Masami Ueda, MD
Hidenari Hirata, MD
Shotaro Sakimura, MD
Yoshiaki Shinden, MD
Hidetoshi Eguchi, MD, PhD
Tomoya Sudo, MD, PhD
Keishi Sugimachi, MD, PhD
Satoru Miyano, PhD
Yuichiro Doki, MD, PhD
Masaki Mori, MD, PhD, FACS
Koshi Mimori, MD, PhD
Publication date: 01-12-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue Special Issue 4/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3740-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Loss of CDCP1 Expression Promotes Invasiveness and Poor Prognosis in Esophageal Squamous Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 4/2014

High STAT4 Expression is a Better Prognostic Indicator in Patients with Hepatocellular Carcinoma After Hepatectomy

Association of miRNA-related Genetic Polymorphisms and Prognosis in Patients with Esophageal Squamous Cell Carcinoma

Silencing of UCHL1 by CpG Promoter Hyper-methylation is Associated with Metastatic Gastroenteropancreatic Well-Differentiated Neuroendocrine (Carcinoid) Tumors

Anti-Prokineticin1 (PROK1) Monoclonal Antibody Suppresses Angiogenesis and Tumor Growth in Colorectal Cancer

Loss of CD44 and SOX2 Expression is Correlated with a Poor Prognosis in Esophageal Adenocarcinoma Patients

Genetic Variations in STK11, PRKAA1, and TSC1 Associated with Prognosis for Patients with Colorectal Cancer